The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute (UT MDAH), an NCI-designated Comprehensive Center, proposes to become a Research Base in the Community Clinical Oncology Program (CCOP). This proposal will encompass both clinical treatment trials and cancer control research. UT MDAH has affiliated with 28 CCOP applicants, and offered 33 treatment protocols and 8 cancer control studies for CCOP participation. The CCOPs have projected an accrual of 979 patients (735.7 credits) to treatment protocols and 1880 subjects (889.4 credits) to cancer control. UT MDAH will accrue 510 subjects (226 credits) to these cancer control studies. A CCOP Central Office with two Data Management Units for clinical trials and cancer control will integrate the data of the CCOPs into the well-established data management systems of the Center. Procedures for patient registration, data collection (including CCOP data forms), data editing for quality control, toxicity surveillance, and pathology review have been developed. CCOP research nurses will serve as a bridge between community CCOP personnel and UT MDAH protocol research nurses. An annual onsite audit by a team that will include a community CCOP member will provide quality assurance, allow consistent evaluation of proficiency status, and strengthen the network. UT MDAH will utilize the full scientific, epidemiologic and statistical resources of its Department of Cancer Prevention and Control to develop a complete cancer control research program. Procedures for protocol identification, and collaboration with basic and clinical scientists both within and outside the Center are well- defined. A cancer control accrual credit system has been implemented. In a pilot project that implemented the CCOP procedures, 31 patients from seven CCOP applicants were placed on UT MDAH treatment and cancer control protocols through the CCOP office. This demonstration of the capacity to easily incorporate CCOP data into existing systems, establishes UT MDAH's ability to serve as a CCOP Research Base.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045809-03
Application #
3558724
Study Section
(SRC)
Project Start
1987-09-01
Project End
1991-05-31
Budget Start
1989-06-01
Budget End
1991-05-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Hospitals
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Levin, Victor A; Ictech, Sandra E; Hess, Kenneth R (2018) Clinical importance of eflornithine (?-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol 7:CNS16
Narayan, Hari K; Wei, Wei; Feng, Ziding et al. (2017) Cardiac mechanics and dysfunction with anthracyclines in the community: results from the PREDICT study. Open Heart 4:e000524
Spencer, Christine N; Lopez, Gabriel; Cohen, Lorenzo et al. (2016) Nurse and patient characteristics predict communication about complementary and alternative medicine. Cancer 122:1552-9
Siefker-Radtke, Arlene O; Campbell, Matthew T; Munsell, Mark F et al. (2016) Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. Urology 89:83-9
Kee, Bryan K; Morris, Jeffrey S; Slack, Rebecca S et al. (2015) A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer 23:661-70
Mitri, Zahi; Karakas, Cansu; Wei, Caimiao et al. (2015) A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs 33:890-4
Minasian, Lori M; Tangen, Catherine M; Wickerham, D Lawrence (2015) Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol 42:748-63
Lewis, Mark A; Zhao, Fengmin; Jones, Desiree et al. (2015) Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. J Pain Symptom Manage 49:1016-24
Oki, Yasuhiro; Ewer, Michael S; Lenihan, Daniel J et al. (2015) Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk 15:152-8
Bilen, Mehmet Asim; Johnson, Marcella M; Mathew, Paul et al. (2015) Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121:69-76

Showing the most recent 10 out of 43 publications